Left ventricular assist devices as destination therapy in stage D heart failure
Rabea Asleh
Sarah S.Schettle
Fazal W.Khan
Sudhir S.Kushwaha
摘要：1 Introduction
Mechanical circulatory support (MCS) has increasingly become an important management opportunity for patients with stage D heart failure (HF) with remarkable impact on patient survival and quality of life.Early clinical trials have demonstrated improved outcomes of durable left ventricular assist device (LVAD) support compared with optimal medical management.[1] As technology advanced,continuous flow LVADs outperformed pulsatile flow devices in clinical trials and the field migrated to HeartMate (Abbott Laboratories,Abbott Park,IL) and HeartWare (Medtronic,Minneapolis,MN) devices due to their clinical superiority.
机标关键词：
论文发表日期：2019-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：9( 592-600 )
英文信息